Cerebras bets that the next wave of AI is all about fast, real-time responses, and its giant “wafer-sized” chip aims to sidestep the slowdown that holds back many GPU setups. Big partnerships and a deep order pipeline could fuel rapid growth, but heavy reliance on a few customers and a looming wave of insider selling could make the ride bumpy.Read more

SpaceX heads into its IPO with fast-growing sales but ongoing losses, as Starlink funds big bets like Starship and its AI buildout. The bigger story may be the short-term market whiplash around the listing and index reshuffling—and how that could spill over into major AI chip and infrastructure suppliers.Read more

Take-Two leans heavily on its next Grand Theft Auto release, with pre-orders and fresh updates expected soon—events that could quickly shift how investors see the business. The story also digs into what could go wrong if the launch slips again, and why the company’s wider lineup and in-game spending help soften the blow.Read more

A major global energy shock is pushing more countries to rely on American oil and gas, and the pipelines and export terminals that move it could be the quiet winners. This view focuses on a fund of “toll booth” businesses that get paid when energy flows, while flagging what could derail the upside.Read more

NVIDIA Corporation is not just another semiconductor company — it is the foundational infrastructure layer upon which the entire AI economy is being built. But even the best companies can be overbought.Read more

The Business in Simple Terms Cheniere operates the largest LNG export terminals in the US — Sabine Pass and Corpus Christi. They liquefy natural gas, load it onto tankers, and ship it to buyers in Europe and Asia under long-term contracts.Read more

Roche is lining up a new wave of potential hit medicines across obesity, cancer, and multiple sclerosis, with many important trial results expected soon. The big question is whether these programs succeed before tougher competition and upcoming patent expiries start to bite.Read more

Ubisoft’s shares look beaten down after a big reset, but a recent Tencent deal suggests its biggest game brands may be worth far more than the market is giving them credit for. The catch is whether heavy losses, tight control by insiders, and staff unrest stop the company from ever turning those assets into value for shareholders.Read more

Early trial results in a pancreatic cancer vaccine show most patients mounting a strong immune response, raising hopes it could help keep the disease from coming back after treatment. The next big readout could be a turning point if the larger study confirms the benefit—and a setback if it doesn’t.Read more